Secret of Novartis’s Commercial Success Is To Keep It Simple
The Swiss giant has raised its forecast for the full financial year, as Cosentyx, Entresto and its oncology portfolio continue to shine, helped by the firm's sleeker selling organization.
More from Earnings
More from Therapy Areas
• By
The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.
• By
Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.
• By
Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.